Parexel International Corp., a Waltham biotechnology services company, said it has purchased software maker Liquent Inc. for $72 million. Liquent makes software used by drug companies to manage regulatory submissions and product registration. The deal will allow Parexel to expand the consulting services it provides to biotech and medical device companies. Parexel helps biotechs bring their drugs to market and helps to maximize sales after drugs become available.